Incanthera plc (AQSE: INC), the specialist company focused on innovative technologies in oncology and dermatology, is pleased to announce the appointment of Caroline Murray as a Non-executive Director with immediate effect.
Caroline brings extensive product management and marketing experience to the Board, having held senior positions in both Novartis and Bristol Myers Squibb (“BMS”). The Board believes Caroline’s experience and skillset is perfectly suited to the company’s near-term goals and ambitions as we look to commercialise our lead product Sol.
Dr. Alan Warrander has advised the Board of his intention to retire to concentrate on his family and leisure interests. This will take effect on 28 February 2022.
Alan joined the team in 2012 as a consultant advising on partnering and licensing and was appointed a Non-executive Director that year, drawing on over 30 years’ experience within global pharma drug discovery and drug development processes, including 21 years with AstraZeneca.
Commenting on the Board changes announced today, Chairman, Tim McCarthy, said:
“We are delighted to announce the appointment of Caroline as a Non-executive Director. Caroline’s experience in product management and marketing demonstrates exactly the skillset that will strengthen the Board as we progress towards the commercialisation of our lead product Sol. We warmly welcome Caroline to the Incanthera team.”
Alan has been integral in Incanthera’s path to date. With his outstanding industry experience and his sound and wise counsel to the Board, we all owe a great debt to Alan’s contribution. Alan will be very much missed by the whole of the Incanthera team. We thank him and wish him a long and happy retirement as he now concentrates on his family and leisure pursuits.”
The following information relating to Caroline Murray is disclosed pursuant to Rule 4.9 of the AQSE Growth Market – Access Rulebook:
Caroline Diana Murray (aged 51) is a director of CDM Consulting (UK) Ltd and has not held any other directorships in the last five years. Caroline Murray does not hold any shares in the Company.
There is no further information to be disclosed pursuant to Rule 4.9 of the AQSE Growth Market Rulebook.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).
The directors of the Company take responsibility for this announcement.
For further enquiries:
Tim McCarthy, Chairman
+44 (0) 7831 675747
Simon Ward, Chief Executive Officer
+44 (0) 7747 625506
Suzanne Brocks, Head of Communications
+44 (0) 7776 234600
Aquis Exchange Corporate Adviser:
Cairn Financial Advisers LLP
Jo Turner/James Lewis
+44 (0) 20 7213 0880
Stanford Capital Partners Ltd
Patrick Claridge/John Howes/Bob Pountney
+44 (0) 20 3815 8880
Notes to Editors
Incanthera is a specialist oncology company focused on innovative technologies in oncology and dermatology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.
The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and the Company is now focussed upon delivering Sol to a commercial partner.
The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.
Incanthera's strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.
For more information on the Company please visit: www.incanthera.com